News
AbbVie is conducting a study titled ‘SUNRISE-UC’ to evaluate the effectiveness and safety of Risankizumab in patients with moderate to severe ulcerative colitis. This real-world study aims to assess ...
TipRanks on MSN6d
AbbVie’s Risankizumab Study: A Potential Game-Changer for Ulcerative Colitis Treatment
Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled ‘A ...
Patients with psoriasis who show an early response to the biologics risankizumab or guselkumab are more likely to have a long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback